MedTrace Logo

Carmat Total Artificial Heart as a Bridge to Transplant in Patients With Advanced Heart Failure

NCT04475393 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 104

Last updated 2026-04-28

No results posted yet for this study

Summary

The objective of this clinical investigation is to evaluate the efficacy and the safety of the Carmat Total Artificial Heart for the treatment of refractory advanced heart failure in transplant eligible patients.

Conditions

  • Advanced Heart Failure

Interventions

DEVICE

Carmat Total Artificial Heart

Heart Replacement Therapy

OTHER

Standard therapy for heart failure

Other approaches in Bridge to Transplantation

Sponsors & Collaborators

  • Carmat SAS

    lead INDUSTRY

Principal Investigators

  • Frederic C Daoud, MD, PhD · Carmat SAS

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-12
Primary Completion
2025-10-24
Completion
2027-04-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04475393 on ClinicalTrials.gov